The Experts below are selected from a list of 132 Experts worldwide ranked by ideXlab platform
Parag Bharadwaj - One of the best experts on this subject based on the ideXlab platform.
-
Phenazopyridine-Induced Sulfhemoglobinemia
The Annals of pharmacotherapy, 2005Co-Authors: Anuradha S Gopalachar, Venita L Bowie, Parag BharadwajAbstract:OBJECTIVE:To report a case of Sulfhemoglobinemia in a patient receiving phenazopyridine for a urinary tract infection.CASE SUMMARY:A 63-year-old white woman presented to the emergency department with complaints of fatigue and bluish discoloration of her body that had gradually progressed over the previous 6–8 weeks. About 4 months prior to presenting to the emergency department, she had started taking phenazopyridine, an over-the-counter medication for symptoms of dysuria. Because the cyanosis did not improve after the patient received oxygen and methylene blue, Sulfhemoglobinemia was suspected and confirmed by spectrophotometer analysis.DISCUSSION:Sulfhemoglobin is a green-pigmented molecule containing a sulfur atom in one or more of the porphyrin rings. It is a rare cause of cyanosis, which is usually drug induced. Sulfhemoglobinemia is suspected when a cyanotic patient has normal to near-normal oxygen tension, laboratory reports of elevated methemoglobin, and does not respond to methylene blue therapy....
Josef T Prchal - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of the methemoglobinemia associated with Sulofenur
Investigational New Drugs, 1994Co-Authors: David C. Molthrop, Richard H. Wheeler, Kelley M. Hall, Josef T PrchalAbstract:A new class of antineoplastic agents, the diarylsulfonylureas entered clinical trials with the testing of Sulofenur (LY186641). Phase I trials and preclinical studies showed the dose limiting toxicity to be methemoglobinemia. We studied the incidence of methemoglobinemia, Sulfhemoglobinemia and cytochrome b5 reductase deficiency in nine consecutive patients enrolled in a phase II trials using Sulofenur. The specific Malloy method as well as clinically standard co-oximeter measurements were used to determine methemoglobin levels and marked discrepancies were noted. One patient with symptomatic methemoglobinemia had enzyme levels and family history consistent with a heterozygous state for a cytochrome b5 reductase deficiency. We conclude that the clinical incidence of methemoglobinemia will de overestimated by co-oximeter measurements but that Sulofenur does produce clinically significant methemoglobinemia in cytochrome b5 reductase deficient patients.
-
Evaluation of the methemoglobinemia associated with Sulofenur
Investigational New Drugs, 1994Co-Authors: David C. Molthrop, Richard H. Wheeler, Kelley Hall, Josef T PrchalAbstract:A new class of antineoplastic agents, the diarylsulfonylureas entered clinical trials with the testing of Sulofenur (LY186641). Phase I trials and preclinical studies showed the dose limiting toxicity to be methemoglobinemia. We studied the incidence of methemoglobinemia, Sulfhemoglobinemia and cytochrome b5 reductase deficiency in nine consecutive patients enrolled in a phase II trials using Sulofenur. The specific Malloy method as well as clinically standard co-oximeter measurements were used to determine methemoglobin levels and marked discrepancies were noted. One patient with symptomatic methemoglobinemia had enzyme levels and family history consistent with a heterozygous state for a cytochrome b5 reductase deficiency.
Thomas G Osborn - One of the best experts on this subject based on the ideXlab platform.
-
acrocyanosis from phenazopyridine induced Sulfhemoglobinemia mistaken for raynaud phenomenon
Jcr-journal of Clinical Rheumatology, 2009Co-Authors: Tanaz A Kermani, Sorin V Pislaru, Thomas G OsbornAbstract:Abstract:Rheumatologists are often asked to evaluate patients with Raynaud phenomenon. Occasionally, an alternate explanation is revealed such as acrocyanosis. Methemoglobinemia and Sulfhemoglobinemia are rare causes of cyanosis that can be medication-induced. Both are known complications of therapy
-
Acrocyanosis From Phenazopyridine-Induced Sulfhemoglobinemia Mistaken for Raynaud Phenomenon
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2009Co-Authors: Tanaz A Kermani, Sorin V Pislaru, Thomas G OsbornAbstract:Rheumatologists are often asked to evaluate patients with Raynaud phenomenon. Occasionally, an alternate explanation is revealed such as acrocyanosis. Methemoglobinemia and Sulfhemoglobinemia are rare causes of cyanosis that can be medication-induced. Both are known complications of therapy with phenazopyridine. We report an unusual case of a 45-year-old woman in whom Sulfhemoglobinemia from chronic therapy with phenazopyridine was misdiagnosed as due to Raynaud phenomenon and limited scleroderma. This case illustrates the importance of taking into account medication-related adverse events when evaluating patients with Raynaud-like phenomenon.
Margaret A. Kenny - One of the best experts on this subject based on the ideXlab platform.
-
A case of Sulfhemoglobinemia and emergency measurement of sulfhemoglobin with an OSM3 CO-oximeter
Clinical chemistry, 1997Co-Authors: Margaret A. KennyAbstract:We describe a case of Sulfhemoglobinemia associated with toxic paint ingestion. Blood gases, oxygen content, and fractional hemoglobin derivatives were assayed with Radiometer 520 and OSM3 instruments. Although the CO-oximeters indicated the presence of sulfhemoglobin (SulfHb), the results were not quantitative. An OSM3 service software program was activated to obtain the actual concentrations of the hemoglobin fractions. Subsequently, we evaluated the performance of the OSM3 service program for the analysis of SulfHb by performing precision studies and comparing OSM3 results with those of an AVL 912 CO-oximeter. Retrospectively, we determined that the patient's specimens contained 6% SulfHb. There was an obvious deviation between standard OSM3 oxyhemoglobin fraction measurements and those obtained by using its service program-the effect of a high SulfHb content.
Anuradha S Gopalachar - One of the best experts on this subject based on the ideXlab platform.
-
Phenazopyridine-Induced Sulfhemoglobinemia
The Annals of pharmacotherapy, 2005Co-Authors: Anuradha S Gopalachar, Venita L Bowie, Parag BharadwajAbstract:OBJECTIVE:To report a case of Sulfhemoglobinemia in a patient receiving phenazopyridine for a urinary tract infection.CASE SUMMARY:A 63-year-old white woman presented to the emergency department with complaints of fatigue and bluish discoloration of her body that had gradually progressed over the previous 6–8 weeks. About 4 months prior to presenting to the emergency department, she had started taking phenazopyridine, an over-the-counter medication for symptoms of dysuria. Because the cyanosis did not improve after the patient received oxygen and methylene blue, Sulfhemoglobinemia was suspected and confirmed by spectrophotometer analysis.DISCUSSION:Sulfhemoglobin is a green-pigmented molecule containing a sulfur atom in one or more of the porphyrin rings. It is a rare cause of cyanosis, which is usually drug induced. Sulfhemoglobinemia is suspected when a cyanotic patient has normal to near-normal oxygen tension, laboratory reports of elevated methemoglobin, and does not respond to methylene blue therapy....
